Table 1 CDH1 promoter methylation distribution according to clinical variables and immunohistochemical analysis in 71 IDCs.
From: CDH1promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer
Variable | CDH1 methylation | p value* | |
|---|---|---|---|
Presence N (%) | Absence N (%) | ||
Age | 0,7842 | ||
≤50 | 19 (76%) | 6 (24%) | |
>50 | 33 (72%) | 13 (28%) | |
Lymph nodea | 0,5049 | ||
≤4 | 42 (75%) | 14 (25%) | |
>4 | 09 (64%) | 5 (36%) | |
Clinical Stage | 0,5268 | ||
I | 9 (90%) | 1 (10%) | |
IIA | 16 (67%) | 8 (33%) | |
IIB | 17 (68%) | 8 (32%) | |
IIIA | 4 (100%) | 0 | |
IIIB | 6(75%) | 2 (25%) | |
Histologic grade | 0,4282 | ||
I | 2 (50%) | 2 (50%) | |
II | 37 (76%) | 12 (24%) | |
III | 13 (72%) | 5 (28%) | |
Immunohistochemical | |||
E-cadherin | 0,1496 | ||
negative/reduced expression (0,1+,2+) | 46 (77%) | 14 (33%) | |
positive (3+) | 6 (55%) | 5 (45%) | |
Her-2 | 0,4339 | ||
negative (0,1+,2+) | 47 (75%) | 16 (25%) | |
positive (3+) | 5 (63%) | 3 (37%) | |
p53 | 1,0000 | ||
negative (0,1+) | 42 (72%) | 16 (28%) | |
positive (2+,3+) | 10 (77%) | 3 (23%) | |
ER | 0,0301 | ||
negative/reduced expression (0,1+,2+) | 37 (82%) | 8 (18%) | |
positive (3+) | 15 (58%) | 11(42%) | |
PgR | 0,3910 | ||
negative/reduced expression (0,1+,2+) | 37 (77%) | 11 (23%) | |
positive (3+) | 15 (65%) | 8 (35%) | |
Ki-67 | 0,0565 | ||
≤25% | 27 (64%) | 15 (36%) | |
>25% | 25 (86%) | 4 (14%) | |